Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis
Open Access
- 7 October 2025
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (3) , 629-640
Abstract
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III trials and other participants from phase I trials ( N = 661). Predicted covariate effects on momelotinib, M21, and total active moiety (TAM)—representing the combined potency‐weighted exposures of momelotinib and M21—exposures following 200‐mg once‐daily dosing were evaluated using a simulation‐based approach. Using sequential modeling, momelotinib was described by a two‐compartment model with six transit absorption compartments and first‐order elimination, and M21 by a two‐compartment model with first‐order elimination. Hepatic function, concomitant CYP3A4 inducers, and concomitant OATP1B1/1B3 inhibitors were significant momelotinib covariates, while baseline creatinine clearance and hepatic function were significant M21 covariates, with cumulative effects on TAM. Exposure–response relationships between the average TAM concentration under actual dosing and key efficacy and safety end points were assessed using data from the 24‐week randomized period of three phase III trials in patients with myelofibrosis ( N = 417). After relevant covariate adjustment, significant positive relationships were identified with spleen volume reduction and transfusion independence (the latter specifically in JAK inhibitor–experienced patients), but not symptom improvement. Greater TAM exposure was significantly associated with lower odds of grade 3/4 anemia and higher odds of any‐grade peripheral neuropathy, although the latter was infrequently observed in phase III trials. There was no significant relationship with grade ≥ 3 thrombocytopenia or any‐grade diarrhea.Keywords
This publication has 34 references indexed in Scilit:
- Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor–Naive or –Experienced Myelofibrosis Treated With MomelotinibClinical Lymphoma Myeloma and Leukemia, 2024
- JAK Inhibitors for Myelofibrosis: Strengths and LimitationsCurrent Hematologic Malignancy Reports, 2024
- Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2Advances in Therapy, 2024
- Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2023
- Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studyThe Lancet, 2023
- Anemia in myelofibrosis: Current and emerging treatment optionsCritical Reviews in Oncology/Hematology, 2022
- A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and managementBlood Reviews, 2021
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With MyelofibrosisJAMA Oncology, 2018
- Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal ImpairmentThe Journal of Clinical Pharmacology, 2017
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre studyThe Lancet Haematology, 2017